Abstract
HIV-associated neurocognitive impairment (HIV-NCI) affects 15%–50% of people with HIV (PWH), despite viral suppression with antiretroviral therapy (ART). HIV neuropathogenesis is mediated, in part, by transmigration of infected CD14 + CD16 + monocytes across the blood-brain barrier (BBB) into the central nervous system (CNS). In the CNS, CD14 + CD16 + monocytes contribute to infection and activation of parenchymal cells, resulting in production of neurotoxic viral and host factors that cause neuronal damage. Mechanisms by which CD14 + CD16 + monocytes contribute to HIV-NCI have not been characterized in a study population of PWH on ART without contribution from confounders that affect cognition (e.g., substance use, hepatitis C virus coinfection). We assessed cognitive function, PBMC transmigration across the BBB, and neuronal health markers in a well-defined cohort of 56 PWH on ART using stringent criteria to eliminate confounding factors. We demonstrated that PWH on ART with HIV-NCI have significantly increased transmigration of their CD14 + CD16 + monocytes across the BBB compared with those with normal cognition. We showed that hypertension and diabetes may be effect modifiers on the association between CD14 + CD16 + monocyte transmigration and cognition. This study underscored the persistent role of CD14 + CD16 + monocytes in HIV-NCI, even in PWH with viral suppression, suggesting them as potential targets for therapeutic interventions.
Funding Information
  • National Institute of Mental Health (R01MH112391,R01DA044584,R01MH131207,R01DA041931,U24MH100931,75N95023C00015,P30MH075673)

This publication has 103 references indexed in Scilit: